News & Updates
Filter by Specialty:
SBRT plus sorafenib improves survival in HCC
Treatment with stereotactic body radiation therapy (SBRT) followed by sorafenib results in better overall (OS) and progression-free survival (PFS), with no increase in adverse events (AEs), compared with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC), as shown in a phase III study presented at the 2023 ASCO GI Cancers Symposium.
SBRT plus sorafenib improves survival in HCC
23 Feb 2023
FMT prevents recurrent C. difficile infection in IBD patients
Patients with inflammatory bowel disease (IBD) who undergo foecal microbiota transplantation (FMT) are less likely to develop recurrent Clostridioides difficile infection (CDI), a study has shown.
FMT prevents recurrent C. difficile infection in IBD patients
23 Feb 2023
Alcohol intake tied to lower H. pylori infection risk, with caveat
A recent meta-analysis has revealed a decreased risk of Helicobacter pylori infection among alcohol drinkers as compared with nondrinkers, with wine and mixed types of alcohol showing greater infection reduction than beer.
Alcohol intake tied to lower H. pylori infection risk, with caveat
22 Feb 2023
FTD/TPI-bevacizumab combo a new SoC for metastatic CRC?
A combination of trifluridine/tipiracil (FTD/TPI) and bevacizumab provided significant survival benefit when used as third-line treatment for refractory metastatic colorectal cancer (CRC) than FTD/TPI alone, findings from the phase III SUNLIGHT study suggest.
